Trials / Completed
CompletedNCT07134738
Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study
Multicenter, Open-label, Non-interventional Study to Assess the Safety and Tolerability of Dimolegin® as a Means of Preventing Thrombotic Complications in the Complex Therapy of Hospitalized Patients With Moderate COVID-19 in a Real Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 184 (actual)
- Sponsor
- Avexima Diol LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, open-label, non-interventional study evaluates the safety and tolerability of oral Dimolegin® (60 mg once daily) for thromboprophylaxis in hospitalized adults (≥18 years) with moderate COVID-19 in real clinical pratice. The primary objective is to assess safety and tolerability of Dimolegin® in preventing thrombotic complications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimolegin | Dimolegin® is administered orally once daily,The recommended dose is 60 mg (six 10 mg tablets) once daily. |
Timeline
- Start date
- 2024-06-07
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
- First posted
- 2025-08-21
- Last updated
- 2026-01-16
Locations
6 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT07134738. Inclusion in this directory is not an endorsement.